February 21, 2026 · Form 4 insider transaction
Cabell Christopher sold 338,282 shares of Inhibikase Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as disposition to the issuer and disclosed on an SEC Form 4, filed 3 days after the transaction.
As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 338,282 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 338,282 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.